

116TH CONGRESS
1ST SESSION

H. R. 4764

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and
for other purposes.

IN THE HOUSE OF REPRESENTATIVES

OCTOBER 18, 2019

Ms. MATSUI (for herself, Mr. BILIRAKIS, and Ms. PINGREE) introduced the
following bill; which was referred to the Committee on Energy and Commerce

A BILL

To reauthorize the Stem Cell Therapeutic and Research Act
of 2005, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Timely ReAuthoriza-
5 tion of Necessary Stem-cell Programs Lends Access to
6 Needed Therapies Act of 2019” or the “TRANSPLANT
7 Act of 2019”.

1 **SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL**
2 **TRANSPLANTATION PROGRAM.**

3 (a) ADVISORY COUNCIL MEETINGS.—Subsection (a)
4 of section 379 of the Public Health Service Act (42 U.S.C.
5 274k) is amended by adding at the end the following new
6 paragraph:

7 “(7) The Secretary shall convene the Advisory
8 Council at least two times each calendar year.”.

9 (b) INCREASING COLLECTION.—

10 (1) TECHNICAL CLARIFICATION.—Effective as
11 if included in the enactment of Public Law 114–104
12 (the Stem Cell Therapeutic and Research Reauthor-
13 ization Act of 2015), the amendment to section
14 379(d)(2)(B) of the Public Health Service Act (42
15 U.S.C. 274k(d)(2)(B)) in section 2(a)(2) of Public
16 Law 114–104 is amended by inserting “goal of in-
17 creasing collections of high quality” before “cord
18 blood units,”.

19 (2) ELIMINATING DEADWOOD.—Subparagraph
20 (B) of section 379(d)(2) of the Public Health Serv-
21 ice Act (42 U.S.C. 274k(d)(2)) is amended by strik-
22 ing the second and third sentences in such subpara-
23 graph.

24 (c) PERIODIC REVIEW OF STATE OF SCIENCE.—Sec-
25 tion 379 of the Public Health Service Act (42 U.S.C.

1 274k) is amended by adding at the end the following new
2 subsection:

3 “(o) PERIODIC REVIEW OF STATE OF SCIENCE.—

4 “(1) REVIEW.—Not less than every two years,
5 the Secretary, in consultation with the Director of
6 the National Institutes of Health, the Commissioner
7 of Food and Drugs, the Administrator of the Health
8 Resources and Services Administration, the Advisory
9 Council, and other stakeholders, where appropriate
10 given relevant expertise, shall conduct a review of
11 the state of the science of using adult stem cells and
12 birthing tissues to develop new types of therapies for
13 patients, for the purpose of considering the potential
14 inclusion of such new types of therapies in the Pro-
15 gram.

16 “(2) RECOMMENDATIONS.—Not later than
17 June 30, 2024, the Secretary shall—

18 “(A) complete the second review required
19 by paragraph (1); and

20 “(B) informed by such review, submit to
21 the Committee on Health, Education, Labor,
22 and Pensions of the Senate and the Committee
23 on Energy and Commerce of the House of Rep-
24 resentatives recommendations on the appro-

1 priateness of the inclusion of new types of
2 therapies in the Program.”.

3 (d) AUTHORIZATION OF APPROPRIATIONS.—Section
4 379B of the Public Health Service Act (42 U.S.C. 274m)
5 is amended by striking “\$33,000,000 for fiscal year 2015
6 and \$30,000,000 for each of fiscal years 2016 through
7 2020” and inserting “\$30,000,000 for each of fiscal years
8 2021 through 2025”.

9 **SEC. 3. CORD BLOOD INVENTORY.**

10 Subsection (g) of section 2 of the Stem Cell Thera-
11 peutic and Research Act of 2005 (42 U.S.C. 274k note)
12 is amended to read as follows:

13 “(g) AUTHORIZATION OF APPROPRIATIONS.—To
14 carry out this section, there is authorized to be appro-
15 priated \$23,000,000 for each of fiscal years 2021 through
16 2025.”.

○